Full text is available at the source.
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells
Improving natural killer cell response to brain tumor stem cells by targeting the αv integrin and TGF-β pathway
AI simplified
Abstract
Glioblastoma stem cells (GSCs) are sensitive to lysis by healthy allogeneic natural killer (NK) cells in vitro.
- GSCs exhibit resistance to standard therapies, contributing to the recurrence of glioblastoma multiforme (GBM).
- Mass cytometry and single-cell RNA sequencing show that NK cells in GBM tumors have an altered phenotype with impaired lytic function compared to NK cells from peripheral blood.
- Direct contact between GSCs and NK cells activates TGF-β via αv integrin, leading to immune evasion by GSCs.
- Combining allogeneic NK cells with inhibitors of integrin or TGF-β signaling, or using TGFBR2 gene-edited NK cells, prevents GSC-induced dysfunction of NK cells and inhibits tumor growth.
- The αv integrin/TGF-β axis may represent a therapeutic target for GBM treatment.
AI simplified